Market News

Iovance Biotherapeutics Tanks as FDA Requests More Data for Lifileuel

Clinical-stage biotechnology company Iovance Biotherapeutics’ (NASDAQ:IOVA) stock is sliding today after its ongoing rolling biologics License Application (BLA) for lifileucel got extended.

The U.S. Food and Drug Administration has provided feedback associated with the supplemental assay validation information and comparability data for the drug which is being targeted for the treatment of advanced melanoma.

The company is working towards addressing the comments and now expects the BLA to be completed in Q1 2023.

Further, a Phase 3 trial of the drug in combination with pembrolizumab in frontline advanced melanoma is anticipated to commence in late 2022.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More